What Is a Contingent Value Right?
A contingent value right is a contractual instrument, granted to a target's shareholders as part of the merger consideration, that entitles them to future payments if defined events occur by set deadlines. Rather than arguing over the value of an uncertain asset, the acquirer pays a base price up front and adds a CVR whose payoff arrives only if the optimistic scenario actually materializes.
CVRs come in two broad flavors. Event-driven CVRs, the dominant type, tie payments to milestones such as regulatory approval of a drug candidate or the outcome of pending litigation. Price-protection CVRs instead compensate target holders if the acquirer's stock trades below a stated level after a stock deal, functioning as a form of downside insurance on the consideration received.
How CVRs Work in Practice
The merger agreement or a separate CVR agreement spells out the triggering milestones, the payment per right, the deadlines, and the acquirer's obligations to pursue the milestones, often framed as a diligent or commercially reasonable efforts standard. Some CVRs are registered and trade on an exchange, giving holders liquidity before the outcome is known, while many others are non-transferable and simply sit as a contingent claim.
Bristol Myers Squibb's 2019 acquisition of Celgene attached a $9.00-per-share CVR contingent on FDA approval of specified pipeline drugs by fixed dates; the rights expired worthless when one approval arrived weeks after its contractual deadline, wiping out roughly $6 billion of potential payments and triggering years of litigation. Sanofi's 2011 purchase of Genzyme similarly used a listed CVR tied to production and sales milestones for the drug Lemtrada.
Why Deals Use CVRs
A CVR is essentially the public-market cousin of an earnout. When the buyer and the target board disagree sharply about a binary outcome, the CVR lets the deal price flex with reality instead of forcing one side to concede. Sellers capture upside they believe in, buyers avoid paying today for results that may never come, and the negotiation can close a gap that a fixed price could not.
The structure carries real frictions. Holders depend on the acquirer's post-closing effort and honesty in pursuing milestones, which invites disputes and lawsuits when payouts are missed, and valuing a CVR requires probability-weighting outcomes much like pricing an option. For students of M&A, CVRs are a memorable example of how deal structuring, rather than price alone, gets transactions signed.
